Schering-Plough and Novartis entered into an agreement to co-develop Novartis’ long-acting beta-agonist, Foradil® (formoterol) with Schering-Plough’s inhaled corticosteroid, Asmanex® (mometasone) for treating asthma and chronic obstructive pulmonary disease (COPD). This article features how this deal would benefit the companies’ respective respiratory franchises and how the product would move in the asthma and COPD markets.